Delrieu, Julien http://orcid.org/0000-0001-8690-8615
Voisin, Thierry
Saint-Aubert, Laure
Carrie, Isabelle
Cantet, Christelle
Vellas, Bruno
Payoux, Pierre
Andrieu, Sandrine
Funding for this research was provided by:
Programme hospitalier de recherche clinique
Article History
Received: 23 June 2020
Accepted: 10 September 2020
First Online: 19 October 2020
Ethics approval and consent to participate
: MAPT-NI study protocol was approved by the French Ethics Committee in Toulouse and AFSSAPS (national agency for the safety of drugs and health products) in February 2009. All MAPT participants gave written informed consent at baseline visit. Participants in MAPT-NI gave separate written consent for PET scans.
: Not applicable.
: SA has received grants from Europe, Ipsen, and France Alzheimer; served as a consultant for Ipsen, Pierre Fabre, Lilly, Nestlé, Sanofi, and Servier; and received non-financial support from Biogen, Nutrition Santé, Pfizer, and Icon, and other forms of support from the AMPA Association. BV receives grants from Pierre Fabre, Avid, Exonhit, AbbVie, Lilly, Lundbeck, MSD, Otsuka, Regeneron, Sanofi, Roche, AstraZeneca, LPG Systems, Nestlé, and Alzheon and personal fees from Lilly, Lundbeck, MSD, Otsuka, Roche, Sanofi, Biogen, Nestlé, Transition Therapeutics, and Takeda. All the other authors declare no competing interests.